Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given a consensus recommendation of “Moderate Buy” by the twenty-two research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, twenty have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $119.50.

A number of equities research analysts have commented on KYMR shares. Oppenheimer raised their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Barclays lifted their price target on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. B. Riley Financial boosted their price target on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Stifel Nicolaus set a $114.00 price objective on shares of Kymera Therapeutics in a research note on Monday, December 8th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near?term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short?term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200?day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit?taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short?term negative sentiment despite company?level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year?over?year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Kymera Therapeutics Trading Down 3.0%

NASDAQ:KYMR opened at $83.52 on Friday. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $103.00. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of -22.70 and a beta of 2.20. The firm has a fifty day simple moving average of $78.75 and a two-hundred day simple moving average of $66.52.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics’s revenue for the quarter was down 60.8% compared to the same quarter last year. During the same period last year, the company earned ($0.88) EPS. Equities analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Jared Gollob sold 49,307 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the completion of the sale, the insider directly owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce Booth sold 229,809 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $91.73, for a total value of $21,080,379.57. Following the completion of the sale, the director directly owned 686,477 shares of the company’s stock, valued at approximately $62,970,535.21. This trade represents a 25.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 561,698 shares of company stock worth $50,388,337. 16.01% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Large investors have recently bought and sold shares of the stock. Federated Hermes Inc. bought a new position in shares of Kymera Therapeutics during the third quarter valued at about $31,622,000. China Universal Asset Management Co. Ltd. increased its stake in Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after buying an additional 10,052 shares during the last quarter. Candriam S.C.A. increased its stake in Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after buying an additional 37,536 shares during the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Kymera Therapeutics by 26.3% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after buying an additional 22,392 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.